‘Ghost networks' are harming patients, but attempts to eliminate them have fallen short
The clock started ticking when Michelle Mazzola's son, Guy, was diagnosed with autism before his second birthday. Doctors told her the sooner Guy received therapy for his nonverbal communication and behavioral challenges, the better chance he had of reaching his full potential — and perhaps entering a kindergarten with neurotypical students.
Like many parents, Mazzola hoped to find therapists who were covered by their insurance. So she consulted a directory of providers listed as 'in-network' on her insurance company's website.
Mazzola spent two weeks calling providers on the list, but found no viable options.
'Probably 50% of the time no one answered the phone or the phone number was wrong,' she said. 'Then you would get people on the phone and they'd say, 'Yeah, we have about a nine-month wait list.''
Watch NBC Nightly News with Tom Llamas tonight at 6:30 p.m. ET/5:30 p.m. CT for more.
She had stumbled upon what's informally known as a 'ghost network' — a directory of providers that are largely unreachable, out of network or don't accept new patients. Studies suggest it's common to encounter these networks while looking for covered care.
By prolonging the search for a provider, ghost networks can delay patients' ability to get diagnosed and treated, or cause them to forgo care altogether. But regulatory efforts to force insurance companies to update their directories or penalize them for inaccurate provider information have fallen short, prompting some patients to turn to the courts.
A class action lawsuit filed last year on behalf of federal employees in New York against Anthem Blue Cross and Blue Shield claims the company's ghost networks amount to deceptive advertising by making people think they're purchasing insurance with an extensive list of in-network providers.
The suit further claims that inaccurate directories help insurance companies 'evade the costs' of covering people's care. It alleges that plaintiffs who could not rely on Anthem's directory were forced to use out-of-network doctors, saddling them with thousands of dollars in extra costs. In moving to dismiss the case, Anthem has argued that federal law pre-empts the plaintiffs from suing as members of the Federal Employees Health Benefits Program.
Mazzola, who lives in Connecticut and runs a construction company with her husband, is not a plaintiff in the suit. She estimated that she pays about $7,000 out of pocket each month for Guy's care, even after appealing denied claims and getting reimbursed for some out-of-network costs. She believes she wouldn't have to pay that sum if the providers in Anthem's directory were available.
'You take it at face value when you're buying a plan that this is what I'm getting,' Mazzola said. 'I would have gladly gone to any of those [in-network] providers if they actually were taking patients.'
If you are dealing with bills that seem to be out of line or a denial of coverage, care or repairs, whether for health, home or auto, please email us at Costofdenial@nbcuni.com.
A spokesperson for Anthem Blue Cross and Blue Shield said the company meets access requirements outlined under state law.
'We also work hard to ensure that our provider directories are up-to-date and as accurate as possible, which requires a shared commitment from providers to update their information when there are any changes,' the spokesperson said.
Anthem said its provider network offers most of the services Guy needs, but due to the specialized nature of those services, it can be challenging to get appointments immediately. The company said it reviewed the list of providers that Mazzola tried to contact and found five errors related to incorrect phone numbers or addresses, which it said it will work with providers to fix.
NBC News reached out to 21 providers listed in Anthem's network, and found 20 either didn't take patients Guy's age or had no availability for months.
Another class action lawsuit filed in April on behalf of state and local employees in New York against Carelon Behavioral Health, which provides health care services through insurance plans, claims that ghost networks delayed plaintiffs' access to mental health treatment. Carelon said it does not comment on pending litigation.
The two class action suits are among the first to challenge insurance companies over ghost networks, said Steve Cohen, a lawyer at Pollock Cohen in New York who is representing the plaintiffs in both cases as well as Mazzola.
'Patients are in need of help,' Cohen said. 'They call provider after provider who are listed in this directory to get no answer, to be told it's not a doctor's office, to be told they don't accept the insurance. It's incredibly frustrating and often complicates getting medical care. It's dangerous.'
Mazzola's experience is familiar to many, regardless of their insurance plan or health issue.
'The vast majority of the time, a doctor's information is not going to be correct,' said Dr. Neel Butala, an assistant professor of medicine at the University of Colorado School of Medicine who co-founded a company that uses artificial intelligence to help large health plans improve provider data.
Butala reviewed physician directories from five large health insurers and found that 81% of entries had inconsistencies, such as address errors or the wrong specialty being listed for a physician. His findings were published in JAMA Network Open. A government review of Medicare Advantage plans found that the share of inaccurately listed provider locations ranged from nearly 5% to 93%, depending on the directory.
Ghost networks can pose a particular challenge to finding mental health providers, many of whom have long patient waitlists or have stopped taking insurance. After calling nearly 400 listed numbers for mental health providers in New York, the state attorney general's office found that 86% were ghost entries. Staffers on the Senate Finance Committee similarly contacted 120 mental health providers listed as in-network by Medicare Advantage plans, and found that ghost entries made up more than 80%.
'In my view, it's a breach of contract for insurance companies to sell their plan for thousands of dollars each month while their product is unusable, unusable due to a ghost network,' Sen. Ron Wyden, D-Ore., said at a Senate hearing on mental health access in 2023.
Anneliese Hanson, who was a network market manager at Cigna Behavioral Health until several years ago, said she felt pressure to make provider networks seem more robust to appeal to current or prospective members.
'If our target was to have 100 autism specialists within a certain [geographic area], we would be working towards meeting that target on paper, rather than actually checking and ensuring that there were 100 autism providers,' Hanson said.
A Cigna spokesperson said the company takes rigorous measures to ensure its directory is updated and accurate, and has a dedicated team of specialists to help patients access behavioral care quickly and conveniently.
In response to Hanson's comments, the spokesperson said: 'These untrue and inflammatory assertions have no basis in reality, neither back then nor today.'
Cohen said that federal and state standards require insurance companies to offer an ample number of in-network health care providers within a defined distance of the patient's home. Those requirements may encourage insurers to pad their directories, he said.
But Butala pushed back on that idea: 'I don't think there's any actually bad actors,' he said. 'I think everyone wants to get this right.'
Butala said there's an incentive for insurance companies to put out the right information, since a bad member experience could cause them to lose customers.
One explanation for ghost networks, he said, is that providers report doctors' information in a way that's conducive for billing, but isn't necessarily accessible to patients. Insurers often receive data that's difficult and time-intensive to comb through, he said.
'I think it's just a really hard problem to solve,' he said.
Mazzola said she and her husband, also named Guy, have been fortunate enough to afford their son's autism therapy so far. The younger Guy, now 2, is not speaking yet but has gotten better at making eye contact and using sign language to communicate words.
But the Mazzolas still feel the insurance system didn't work for them as promised.
'You pay for insurance your whole life, hoping [a diagnosis] never happens, but when it does, that you can put your head on the pillow at night knowing they're going to be there for you. And that just wasn't the case,' Guy Mazzola said.
Legal and medical experts say some protections against ghost networks exist, but aren't consistently enforced. Under the No Surprises Act, a federal law that took effect in January 2022, private health plans are required to verify and update their provider directories at least every 90 days. If a member receives out-of-network care because the directory information was inaccurate, insurance companies must reimburse them for any costs that exceed the in-network price.
Patients can also file complaints to state regulators, who have the authority to fine companies for directory errors. But a ProPublica investigation last year determined that such fines are rare. In an average year, fewer than a dozen fines are issued by insurance regulators for directory errors, the investigation found — and even then, the penalties are small.
One solution that might reduce the prevalence of ghost networks is a centralized directory of providers that all health plans could refer to. But health policy experts see that as a long-term goal that would be difficult to implement.
Butala said AI can help insurers scrub their directories for errors.
'I don't think health plans are skimping on throwing people at the problem,' he said. 'I think they've been throwing too many people at the problem, and now they realize maybe AI can actually make it better.'
But the Mazzolas also think insurance companies should be willing to pay more providers, so it's not a challenge to offer services in-network.
'I'm not anti-business. I'm not anti-profit, but there's an ethical side of it, too,' Michelle Mazzola said. 'Something needs to be done.'
This article was originally published on NBCNews.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire
Yahoo
17 hours ago
- Yahoo
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Fireside chat scheduled for Tuesday, June 10, 2025, at 10:40am ET. NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. CONTACT: Investor RelationsEmail: ir@ (8489), Option 4 Media Relations:Email: media@ (8489), Option 6Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Indianapolis Star
18 hours ago
- Indianapolis Star
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6 th at 11:20 AM ET / 10:20 AM CT – Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6 th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS). 9.1 point average rVCSS improvement among the responder cohort. A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS). Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size. Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym). Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. 'These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options,' said Robert Berman, enVVeno Medical's Chief Executive Officer. 'Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option.' Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, ' Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve' today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the 'Company') related thereto contain, or may contain, among other things, certain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as 'projects,' 'may,' 'will,' 'could,' 'would,' 'should,' 'believes,' 'expects,' 'anticipates,' 'estimates,' 'intends,' 'plans,' 'potential' or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. MEDIA CONTACT: Glenn Silver, FINN Partners (973) 818-8198 SOURCE: enVVeno Medical Corporation View the original press release on ACCESS Newswire